

## Original paper

# Antihypertensive Drugs patterns in Diabetes Mellitus and Their Impact on Glycemic Control.

Amir Omran<sup>^\*</sup>

<sup>^</sup>College of Medicine/ University of Kerbala / Karbala/ Iraq

## Abstract

**Background:** Hypertension management is paramount important in diabetic patients for cardiovascular events reduction. The utilization patterns of antihypertensive agents in diabetic patients must be consistent with recommended guidelines practice to produce a positive metabolic effect on glycemic control with proper control blood pressure and good compliance.

**Objectives:** The study aims to evaluate utilization prescribing pattern of five groups of antihypertensive agents among Type2 diabetic hypertensive patients and to explore the adherence to prescribing existing guidelines and their impacts on glycemic control.

Design: retrospective descriptive ,cross sectional study

**Patients and Methods:** A total of 230 Hypertensive Type2 diabetes patients on diet , Metformin and sulphonylureas drugs were enrolled in the study in diabetic clinic at Imam Al-Hussien medical city . The study was done between Jan 2009 And Jan 2014. The attendants' patients used five groups of the Anti-Hypertensive agents in single or in combinations patterns Angiotensin Converting enzymes inhibitor(ACEI), Angiotensin Receptor Blocker(ARB), Calcium Channels Antagonist(CCA), Beta Blocker(BB), Diuretics(Thiazide)). The study followed five groups of antihypertensive drugs for three months to evaluate prescribing patterns accordance to the evidence base guidelines and compare their impact on glycemic control. The study include gender, Age, age distribution, Glycemic control. The study excluded endocrine, liver, and renal diseases, and patients using steroids.

**Results:** The majority of the patients on Antihypertensive drugs 191 patients (83%) were receiving monotherapy including ACEI 77 ( 33.5%) patient, ARB 46( 20%)patient, BB 60(26.1%) patint, CCB 6 patients (2.6%),Thiazide 2 (0.9%) patients, while two or three drugs combined patterns formed 39 ( 16.95%) patient.

The proper and adequate glycemic control of both genders are 25.2% . The proper glycemic control of males 40.9% and in females16,7%(  $P<0.05$ ) , There were no significant differences of the impact on glycemic control compared between five groups, ACE or ARB compared with single BB (Atenolol, Metaprolol) or CCB, Diuretics, as monotherapy or polytherapy combination patterns.

**Conclusion;** The utilization patterns of Antihypertensive agents (ACEI,ARBS,BBS) were more commonly prescribed followed by CCB, Thiazide Diuretics ,irrespective of mono or polytherapy. The majority of the patients were on monotherapy pattern.

There was no significant difference among the five groups of Antihypertensive drugs regarding the impact on glycemic control.

\*For Correspondence: E-Mail amiromran1953 @Yahoo Com

**Keywords:** Type2 Diabetes mellitus, Antihypertensive drugs( AHT),Glycemic control, Hypertension.

## Introduction

Hypertension (HT) is more common in Diabetics than non-diabetics patients . An aggressive approach to the diagnosis and treatment of Hypertension in patients with diabetes is required in order to substantially reduce the incidence of both macro vascular and micro vascular complications <sup>(1)</sup>. The antihypertensive (AHT) agents used in diabetic patients should not only aim to control hypertension (HT) but also at preventing and delaying the development of complications<sup>(2)</sup>. The majority of hypertensive diabetic patients will require two or more drugs to achieve proper blood pressure (BP) control <sup>(3,4,5)</sup>, because some studies showed that even adherence to existing evidence base guidelines, high proportion of uncontrolled B.P found<sup>(6)</sup>. It was found that combining AHT drugs from two different classes lowered BP five times more than doubling the dose of single agent<sup>(7)</sup>, in addition to synergistic BP lowering combination therapy allows for lower dosage requirements of each individual agent. This, in turn leads to decreased side effects, thereby improving compliance <sup>(8)</sup>.

Conventionally prescribing practice of antihypertensive (AHT) drugs according to recommended guidelines in Diabetes having positive metabolic effect were ACEI-(captopril, Enalapril, Ramipril) and ARB-(Valsartan, Losartan, Candasartan) to achieve proper glycemic control comparing with negative metabolic drugs , Beta blockers-(Atenolol, Metaprolol) and diuretics (Thiazide) leading to improper glycemic control while calcium antagonist have neutral effect <sup>(5,9,10,11)</sup>. New onset diabetes induced by diuretics or B.Bs were not considered as diabetes because Post prandial glycaemia does not usually exceed 200mg/dl and patient shows no evidence of any vascular complications<sup>(12)</sup>.

ACEI and an ARB improve tissue blood flow and insulin release and enhancing insulin receptors producing proper diabetic control, while negative metabolic drugs worsen glycemic control by increasing insulin resistance and decrease insulin secretion by diminish blood flow to Beta cells of the pancreas and hypokalemia respectively<sup>(10)</sup>. Hypertensive patients who are receiving BB had 28% high risk of subsequent Diabetes, also each 0.5mg/L decrease in serum K during first year of treatment was associated with 45% high adjusted Diabetes risk <sup>(13)</sup>. The negative metabolic effects of BB and diuretics depends on the duration (>4 Wks) and the doses (atenolol 50-100 and thiazide 20-50 mg) to achieve effective anti HT control, but this adverse effect must be weighed against proven benefit of BB or diuretics in reducing risk of cardiovascular events <sup>(14)</sup>. Most of the studies showed that small doses of (BBs, Diuretics) have no significant effects on glycemic control <sup>(15)</sup>, while combination of low dose diuretics with ACEI, ARB or CCB may prevent the metabolic deleterious effects of thiazide diuretics<sup>(16)</sup>. Anyway the use of medications that can worsen glycemic control are unnecessarily because other treatment options exists<sup>(17)</sup>.

## Patients & methods

The study was retrospective, descriptive, cross sectional, conducted among patients attending Diabetic clinic in Imam Al-Hussien medical city in Kerbala governorate in period between (1-1-2009) and (1-1-2014), the study involved T2DM at age of 40Y and older.

Total patients attending Diabetic clinic were 750 patients whom were under my care— only, (total patients were attending Diabetic clinic were 4000 patients) written consent was taken from each patient. Every patient had individuals case sheet.

The study discovered 230 hypertensive patient out of 750 on five groups of anti-Hypertensive drugs encompassed of ACEI, ARB, Calcium channel blocker and Beta blocker, Diuretics (Thiazide).

Total of 230 patients were included in the study, who used single anti-hypertensive drug (ACEI or ARB or BB, CCB, diuretics) or polytherapy were considered a combination of two or three drugs from different classes at any dose and frequency were enrolled in the study. The study compared between the impact of monotherapies or polytherapy patterns on glycemic control (both positive and negative metabolic effects). The following drugs were used in the present study, ACEI (captopril 50-150 mg or enalapril 5-20mg, Lisinopril 5-40mg) or ARBS (valsartan 80 - 160mg, candesartan 8-16 mg or losartan 50-100 mg), B.Bs (Atenolol 50- 100mg, Metoprolol 50- 100mg), CCBs (Amlodipine 5-10mg), Thiazide (12.5- 50mg). All these patients had good compliance to their medications (Anti Diabetic and Anti-hypertensive drugs).

All T2DM patients received metformin (500- 850mg×2) and sulphonylureas group (Glimepiride 2-6mg or Glibenclamide 5 -15mg), 36pt (15.7%) added insulin to their oral therapy of T2 DM to achieve proper glycemic control. The study followed the patients for three months.

Diagnosis of HT in T2DM was  $\geq 130/80$  in sitting position using two office visits over one month period according to guidelines of hypertension in diabetes (according to JNC7 report) <sup>(18,19)</sup>.

Diagnosis of DM were done by symptoms of diabetes plus fasting blood sugar (8-12hr) for 2 visits of  $\geq 126$ mg/dl or 2 hours postprandial  $\geq 200$ mg/dl plus HbA1c  $\geq 6.5\%$ . (20,21). (Fasting was defined as no caloric intake for at least eight hr).

The study included also gender and age, age distribution, the impact of AHT drugs on glycemic control.

Diet regimen paper used by all groups of attending patients in diabetic clinic.

The study registered HbA1c at the first time of attending Diabetic clinic and after three months, while FBS and 2 hours postprandial blood sugar were measured every day.

### Exclusion criteria

1. Smoking
2. Any patient with poor compliant to the treatment.
3. Patient utilized corticosteroid and Phenytoin, Niacin, Olanzapine, Clozapine.
4. Endocrine diseases acromegaly, Cushing syndrome, Renal, Liver diseases, Thyrotoxicosis, Pheochromocytoma
5. Gestational DM
6. Type 1 DM

### Results

The mean age of the patients was 54.93 year  $\pm$  9.88 year and the comparable figures for males were 53.05 year  $\pm$  10.06 year and females 58.36 year  $\pm$  8.58 year. The histogram of patients' age distribution is shown in Figure 1. No significant difference were found in the age distribution between males and females ( $p > 0.05$ ). There were no significant difference between age distribution and glycemic control ( $p > 0.05$ ) (tab1)

A total of 230 HT T2 diabetic patient were included in the study. The majority of the patients were considered improper glycemic control (172 patients, 74.8%) while 25.2 % have adequate glycemic control. However a significantly higher proportion of males have proper Glycemic control 40.9 % than females were 16.78 % ( $P < 0.05$ ) (tab2). Males formed the majority of the sampled patients (149 male

patient (63.3%) and 81 female (36.7%) patient ( $P < 0.05$ ). (tab2)

Most of the patients, 191 (83%) patient utilize drugs by monotherapy pattern include ACEIS 77(33.5%), ARBS 46 (20%) patient, BBs 60 (26.1%) patient, CCB 6 (2.6%) patients, Thiazide 2 (0.9%) patients (tab3). The utilization monotherapy of ACEI, ARBs occupied the majority of AHT drugs (53.5%), The least monotherapy utilization are CCB and Thiazide 2,6%,0.9% respectively, while polytherapy formed 39pt(16.9%) divided into two drugs combination 34patient(14.7%) and three drugs combinations formed 5 patients (2.2%) tab3. The utilization two drugs polytherapy of ACEIS or ARBs with thiazide were 1 patient (0.4%), seven patients (3%) respectively. The most common two drugs polytherapy utilization are ACEI+CCA and ARBS+Thiazide (2.6%,3%) respectively.(tab3). In our present study there were no significant difference on impact of glycemic control ( $p > 0.05$ ) between single positive metabolic effect drug in guidelines (ACE or ARB) or their combination s compared with single or combination patterns of


traditional negative metabolic effect drug (BB, Thiazide) and CCB (tab 4,5,6).

## Discussion

The study shows that 30.6 % of attending T2DM patients to the diabetic clinic are hypertensive compatible to other studies in Iraq<sup>(22)</sup> and differ from others studies (India 47.5% , KSA 54.9%)<sup>(6, 23)</sup>.

The mean age of both gender was 54.93 year Compatible to the other studies as in king Saudi Arabia(KSA)<sup>(24)</sup>. The peak of age distribution for D.M patients(46–55y were 37% and 56– 65y were 37.8%) which compatible with most studies<sup>(25)</sup>. The study shows no significant association between age and glycemic control (Tab1). Males formed the majority of the patients (males 63.3%, females 36.7%) which similar to other studies<sup>(24,26)</sup>.

The study discovers gloomy Picture related to poor glycemic control (73.8%) in patients using five groups of antihypertensive drugs which indicate poor health diabetic care program and social Health education. This result compatible with Kindy (Baghdad) and Basra Diabetic centers.<sup>(22)</sup>



**Figure 1.** The age distribution of diabetic patient in Diabetic clinic at Imamm Al Hussain Medical city in Kerbala .

**Table 1.** The age distribution by Glycemic control among diabetic patient in Diabetic clinic at Imamm Al Hussain Medical city in Kerbala (n=230)

Age category	Diabetes mellitus control		Total
	Controlled Diabetes	Uncontrolled Diabetes	
25-45 year	10 (29.4%)	24 (70.6%)	34 (100.0%)
46-55 year	19 (22.4%)	66 (77.6%)	85 (100.0%)
56-65 year	21 (24.1%)	66 (75.9%)	87 (100.0%)
>65 year	8 (38.1%)	13 (61.9%)	21 (100.0%)
<b>Total</b>	58 (25.6%)	169 (74.4%)	227 (100.0%)

 $\chi^2 = 2.55, p=0.466$ **Table 2.** The gender distribution of Glycemic control among patient in Diabetic clinic at Imamm Al Hussain Medical city in Kerbala .

	Diabetes		Total
	Controlled	Uncontrolled	
<b>Males</b>	33 (40.7%)	48 (59.3%)	81 (100.0%)
<b>Females</b>	25 (16.8%)	124 (83.2%)	149 (100.0%)
<b>Total</b>	58 (25.2%)	172 (74.8%)	230 (100.0%)

 $\chi^2=15.98 ; p<0.05$ **Table 3.** Antihypertensive regime distribution among diabetic patients Al Hussain Teaching hospital in Kerbala medical city (n=230)

Regime	Antihypertensive drug type	Frequency	Percent
Mono-therapy	ACE	77	33.5
	ARB	46	20
	CCA	6	2.6
	BB	60	26.1
	Thiazide	2	0.9
	Total	191	83.0
Di-therapy	ACE+CCA	6	2.6
	ACE+BB	7	3
	ACE+Thiazide	1	0.4
	ARB+CCA	2	0.9
	ARB+BB	5	2.2
	ARB+Thiazide	7	3
	CCA+BB	4	1.7
	BB+Thiazide	2	0.9
	Total	34	14.8
Tri-therapy	ACE+CCA+BB	1	0.4
	ARB+CCA+BB	2	0.9
	ARB+BB+Thiazide	2	0.9
	Total	5	2.2
Grand Total		230	100

**Table 4.** The distribution of antihypertensive drug use with impact on glycemic control among diabetic patient in Diabetic clinic at Imamm Al Hussain Medical city in Kerbala (n=230)

Regime	Antihypertensive drug type	Controlled Frequency	Percentage	Uncontrolled	Total Freq.	Percentage
Mono-therapy	ACE	20	26.0	57	74.0	77
	ARB	11	23.9	35	76.1	46
	CCA	1	16.7	5	83.3	6
	BB	13	21.7	47	78.3	60
	Thiazide	2	100.0	0	0.0	2
	Total	47	24.6	144.0	75.4	191.0
-Di-therapy	ACE+CCA	3	50.0	3	50.0	6
	ACE+BB	1	14.3	6	85.7	7
	ACE+Thiazide	0	0.0	1	100.0	1
	ARB+CCA	1	50.0	1	50.0	2
	ARB+BB	1	20.0	4	80.0	5
	ARB+Thiazide	0	0.0	2	100.0	2
	CCA+BB	2	50.0	2	50.0	4
	BB+Thiazide	0	0.0	2	100.0	2
	Total	8	35.1	14.8	64.9	22.8
Tri-therapy	ACE+CCA+BB	1	100.0	0	0.0	1
	ARB+CCA+BB	0	0.0	2	100.0	2
	ARB+BB+Thiazide	0	0.0	2	100.0	2
	Total	1	31.3	2.2	68.8	3.2
Total		85	49.4	100	58.1	172

**Table 5.** The distribution of Glycemic control by type of antihypertensive drug (single and improper combinations)

	Controlled Diabetes	Uncontrolled Diabetes	Total
Proper Single and Combinations	31 (25.2%)	92 (74.8%)	123 (100.0%)
Improper Single Antihypertensive	27 (25.2%)	80 (74.8%)	107 (100.0%)
Total	58 (25.2%)	172 (74.8%)	230 (100.0%)

chisq=0.00,p=.996

**Table 6.** The distribution of diabetes control by type of antihypertensive drug combinations (Proper and improper combinations)

	Controlled Diabetes	Uncontrolled Diabetes	Total
Proper Combinations	31 (25.2%)	92 (74.8%)	123 (100.0%)
Improper Antihypertensive	27 (25.2%)	80 (74.8%)	107 (100.0%)
Total	58 (25.2%)	172 (74.8%)	230 (100.0%)

chisq=0.167 P=.683

The study shows high prevalence of adequate glycemic control in males than females 63-7% and 37.3% respectively ( $p < 0.05$ ) compatible with other study<sup>(27)</sup>, this may be explained as the myths and misconceptions about diabetes and its

management were more common in females. These misconceptions and inadequate knowledge had a significant influence on diabetic control<sup>(28)</sup>. It is imperative for physicians to understand myths and misconceptions in a particular

community about diabetes to improve patients care.

The present study shows the majority of prescribing of antihypertensive drugs utilization were monotherapy (83%) (ACEIs, ARBs, Beta-blockers, CCB, Thiazide diuretics), in comparison with polytherapy combinations enrolled all five groups utilization were (16.95%) (tab 3) while most of other studies have opposite results as polytherapy formed more than 50%(29), while other studies had similar results<sup>(30)</sup> that may explain high prevalence of uncontrolled B.P in Kerbala prevalence (not measured) because the prescribing pattern reflected the physicians attitude toward the disease and their therapeutic knowledge<sup>(7,8)</sup>.

In the present study ACEs, ARBs, BBs were more commonly prescribed drugs, followed by CCAs and Thiazide irrespective of mono or polytherapy (tab3) that were inconsistent with evidence guidelines and different from other studies in which diuretics formed 41% of AHTdrugs<sup>(29)</sup>. The study show high prevalence of ACEs and ARBs utilization (53.5%) ,BBs formed (26%) which were in accordance with Joint National committee (JNC7) guidelines in reducing incidence of CVD, stroke and Reno protection that considered as area of improvement in AHT therapy for diabetic patients<sup>(31)</sup>. while in new guidelines criteria (JNC8) in which BBs were shifted to 2<sup>nd</sup> or 3<sup>rd</sup> line AHT treatment<sup>(32)</sup>. In our study the combined ARB+CCB formed (0.9%) which is not consistent with evidence based practice guidelines as they are potentially antiproteinuric effect in patients with type 2 diabetic nephropathy, even when their renal function is reduced<sup>(33)</sup>.

The present study shows low prevalence utilization of CCB (2.6%) and Thiazide (0.9%) that were not consistent with evidence of guidelines in comparison with other most studies' (in KAS, CCB 43%,

ACEIs 36.2%, ARBS 34.9%, Diuretics 34.2%,BBS 16.2%)<sup>(34)</sup>. This mean that the core results of our study generally not compatible with recommended accordance to JNC7 andJNC8 guidelines. This result of low prevalence of thiazide utilization which consistent with evidence based traditional recommended guidelines antihypertensive drugs in diabetes avoiding diuretics (thiazide) as they cause hypokalemia which lead to insulin resistance and decrease insulin secretion<sup>(10)</sup>, while in JNC7 guidelines ACEIs plus diuretics are widely used to achieve blood pressure control in 80 % of the patients comparison with other studies<sup>(35)</sup>.

ONEAST study results confirm that ARB+Diuretic combinations reduce BP further than monotherapies in HT diabetic patients with safety profile<sup>(33)</sup>. The study shows limited utilization of CCB in comparison with high prevalence used in other studies as it traditionally considered neutral drug on glycemic control<sup>(10,11,12)</sup>. The wide used of BBs (26%) related to their low cost and old famous drug. This result was not consistent with new JNC8 recommended guidelines because BBs worsen glycemic control and abolished symptoms of Hypoglycemia and causing insulin resistance with weight gain<sup>(32,36)</sup>.

The important finding in this study was proving that no significant difference seen in glycemic control among two groups of Anti-hypertensive drugs( ACEI , ARB) compared with Beta blockers, CCBs, thiazide type diuretics or their combinations especially When the later were used in lower doses which match with most of the studies<sup>(14,37,38)</sup>.

## Conclusion

In the present study, the monotherapy represent the majority of prescribing patterns of antihypertensive agents .The single drug used in large proportion of diabetic hypertensive patients were ACEI, ARB, BB followed by CCBs and diuretics

irrespective to mono or polytherapy which is generally not consistent with recommended evidence based practice guidelines. Areas of improvement include increasing ACEIs, ARBs used. The study proved that there were no significant difference among ACEIs, ARBs comparing with BBs, thiazide diuretics, CCBs in mono or polytherapy patterns regarding to the impact of proper glycemic control.

## References

1. Shastry R, Adhikari MP, Ullal SD, Kotian S. Usage of diuretics among diabetic-hypertensive patients. *Asian Journal of Medical Sciences*. 2014 Sep 15;6:14-7.
2. Patel BM, Mehta AA. Choice of anti-hypertensive agents in diabetic subjects. *Diabetes and Vascular Disease Research*. 2013 Sep 1;10:385-96.
3. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. *Hypertension*. 2002 Dec 1;40:781-8.
4. Sowers JR, Reed J. 1999 Clinical Advisory Treatment of Hypertension and Diabetes. *JOURNAL OF CLINICAL HYPERTENSION-GREENWICH*. 2000 Mar;2:132-3.
5. Alvin C. powers diabetes mellitus. *Harrison principles of internal medicine-volume II* , 17th edition 2008.
6. Dhanaraj E, Raval A, Yadav R, Bhansali A, Tiwari P. Prescription pattern of antihypertensive agents in T2DM patients visiting tertiary care centre in North India. *International journal of hypertension*. 2012 Dec 18;2012.
7. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *The American journal of medicine*. 2009 Mar 31;122:290-300.
8. Vogel Anderson KL, combination thrapy hypertension management. *Us pharma*. 2012;37:46-50.
9. David F. Black burn pharma D and Thomas and wilson M.D. *FRCP C2. (an) J cardiol*-2006 march, 23,209-233.
10. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. *Diabetes care*. 1991 Mar 1;14:203-9.
11. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. *American journal of hypertension*. 2001 Nov 1;14:310S-6S.
12. Mandal AK, Hiebert LM. Is Diuretic-Induced Hyperglycemia Reversible and Inconsequential?. *Journal of Diabetes Research and Clinical Metabolism*. 2012 Jul 12;1:4.
13. Ehud Grossman, diuretic increase risk a new onset DM. *Journal diabetic care*.2011 may 34.
14. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. *New England Journal of Medicine*. 2000 Mar 30;342:905-12.
15. Konzem SL, Devore VS, Bauer DW. Controlling hypertension in patients with diabetes. *American family physician*. 2002 Oct;66:1209-14.
16. Rebold G. choice of ACEi combination in hypertensive patients with T2 diabetes-update after recent clinical trial. *vasc –health risk management* 2009;5411–27
17. RICARDO C. Hood. use a diuretics to treat hypertension in diabetic persons *Am.Fam physician* 2004 November 1;70;1646-1648.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*. 2003 Dec 1;42:1206-52.
19. Ebrahim A.Babsis. Management of hypertension -An overview of JNC7 Monday november 1-2004.
20. B.M. Frier, M.Fisher diabetes mellitus-Davidson-principles and practice of medicine 21st edition.
21. Escobar C, Barrios V, Calderón A, Llisterri JL, García S, Rodríguez-Roca GC, Matali A. [Diabetes mellitus in hypertensive population attended in Primary Care in Spain. Blood pressure and lipid control rates]. *Revista clinica espanola*. 2007 May;207:221-7.
22. Showky kazala , Conference of The world day of DM in 14/11/2015 Baghdad, prevalence of hypertension in Diabetic patients in Iraq.Almostenseria Diabetic center
23. Ahmed. G. Elzubier hypertension in diabetic regiistrated in primary care center in MAKAH- saudia arabia-J-Family community-Med-2000 Dec.7;23-28.
24. Khalid A.AL qurashii,Khalid S-Aljabriand Samia-Bokhari - prevalence of DM in saudi community.*Journal list Ann-saud-Med*.v.31; Jan-Feb 2011; 19-23 .
25. Hilary King-Global lourden of diabetic prevalence of numerical estimation and projection , *A.M.A* 1945-2025.



26. Mansour. M. Mohammed A. Alnoza, Mohamed AL maatouq diabetes mellitus in Saudia-Arabia 1 July 2004-saudi medical Journal 25; 1603-1601.
27. Miyan Z, Basit A, Ahmedani MY, Fawwad A, Hydrie MZ, Ali SM. Glycemic control, hypertension and chronic complications in type 2 diabetic subjects at a tertiary care unit of Karachi, Pakistan. Diabetic Medicine. 2006 Dec 1;23:536.
28. Alsunni AA, Albaker WI, Badar A. Determinants of misconceptions about diabetes among Saudi diabetic patients attending diabetes clinic at a tertiary care hospital in Eastern Saudi Arabia. Journal of family & community medicine. 2014 May;21:93.
29. Rimoy GH, Justin-Temu M, Nilay C. Prescribing patterns and cost of antihypertensive drugs in private hospitals in Dar es Salaam, Tanzania. East and Central African Journal of Pharmaceutical Sciences. 2008;11.
30. MALLAN. JIT-Kon war-prescribing pattern of hypertensive drugs in essential hypertension-in medicine outpatient department in tertiary care hospital Vol.7,supp12,2014.
31. Bethesda -The seventh report of joint National committee on prevention detection, evaluation, and treatment of high blood pressure education program 2004-report No:04-5230.
32. Michael R. page-pharma D:RPH JNC8 , hypertension guidelines An in-Depth American Medical association on december18-2014.
33. Kalra S. Kalra B,Aqrawal N. combination therapy in hypertension; An update diabetes Metabolic syndrome 2010;2:44-doi 10.1186/1758,5996-2-44.
34. Sirajudeen Shaik Alavudeen,Khaled Mohammed Alkhali,Shaik MohammedAsif Ansari-Noohu Abdulla Khan.Prescribing pattern of antihypertensive drugs in diabetic patients of southern province,Kingdom of Saudi Arabia Ars pharm.2015,56:109 –114
35. Skolnik NS,Beck JD,Clark M. combination drugs recommendation for use Am-Fam-physician 2000-61:3049-56.
36. ALLAD-Struthor-Michael B. Murrphy, glucose tolerance during hypertensive therapy in patients with D.M, department of medical pharmacology.Royal post graduate clinical school-London.july 17th-2015.
37. Gress TW Nengl J.medicine.hypertension and antihypertensive therapy as risk factors for T2 DM. Atherosclerosis risk in communities study 2000 march 30,342; 905-12.
38. Dash ,Thiazide must be included as part of drug regeim for most patients with diabetes diet. App to stop hypertension 21/10/2014.